SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia treated with immunoglobulin and argatroban

Lancet. 2021 Jun 26;397(10293):e19. doi: 10.1016/S0140-6736(21)01238-1. Epub 2021 Jun 11.

Authors

Katharina Guetl¹, Thomas Gary², Reinhard B Raggam¹, Johannes Schmid³, Albert Wölfler⁴, Marianne Brodmann¹

Affiliations

¹ Division of Angiology, Medical University of Graz, Graz, Austria.
² Division of Angiology, Medical University of Graz, Graz, Austria. Electronic address: thomas.gary@medunigraz.at.
³ Division of General Radiology, Department of Radiology, Medical University of Graz, Graz, Austria.
⁴ Division of Haematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

No abstract available

Publication types

Case Reports

MeSH terms

Antithrombins / therapeutic use
Arginine / analogs & derivatives
Arginine / therapeutic use
COVID-19 / prevention & control*
COVID-19 Vaccines / adverse effects*
Female
Humans
Immunoglobulins, Intravenous / therapeutic use
Immunologic Factors / therapeutic use
Middle Aged
Pipecolic Acids / therapeutic use
Purpura, Thrombocytopenic / chemically induced*
Purpura, Thrombocytopenic / drug therapy*
Purpura, Thrombocytopenic / immunology
SARS-CoV-2
Sulfonamides / therapeutic use

Substances

Antithrombins
COVID-19 Vaccines
Immunoglobulins, Intravenous
Immunologic Factors
Pipecolic Acids
Sulfonamides
Arginine
argatroban